IZTC Quote, Financials, Valuation and Earnings

AIM ImmunoTech has a net margin of -- compared to Invizyne Technologies's net margin of -10571.43%. Invizyne Technologies's return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.

Invizyne Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand AIM ImmunoTech has an analysts' consensus of -- which suggests that it could grow by 1310.26%. Given that AIM ImmunoTech has higher upside potential than Invizyne Technologies, analysts believe AIM ImmunoTech is more attractive than Invizyne Technologies.

Invizyne Technologies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of -0.363, suggesting its less volatile than the S&P 500 by 136.304%.

Invizyne Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invizyne Technologies pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

Invizyne Technologies quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Invizyne Technologies's net income of -$1.4M is higher than AIM ImmunoTech's net income of -$3.7M. Notably, Invizyne Technologies's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invizyne Technologies is -- versus 53.59x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI has a net margin of -- compared to Invizyne Technologies's net margin of --. Invizyne Technologies's return on equity of -- beat CEL-SCI's return on equity of --.

Invizyne Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI has an analysts' consensus of -- which suggests that it could grow by 1004.76%. Given that CEL-SCI has higher upside potential than Invizyne Technologies, analysts believe CEL-SCI is more attractive than Invizyne Technologies.

Invizyne Technologies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.593, suggesting its less volatile than the S&P 500 by 40.711%.

Invizyne Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invizyne Technologies pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Invizyne Technologies quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Invizyne Technologies's net income of -$1.4M is higher than CEL-SCI's net income of -$6.9M. Notably, Invizyne Technologies's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invizyne Technologies is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -- compared to Invizyne Technologies's net margin of -416.75%. Invizyne Technologies's return on equity of -- beat IGC Pharma's return on equity of -137.43%.

Invizyne Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand IGC Pharma has an analysts' consensus of -- which suggests that it could grow by 914.89%. Given that IGC Pharma has higher upside potential than Invizyne Technologies, analysts believe IGC Pharma is more attractive than Invizyne Technologies.

Invizyne Technologies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.8%.

Invizyne Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invizyne Technologies pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Invizyne Technologies quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $412K. Invizyne Technologies's net income of -$1.4M is higher than IGC Pharma's net income of -$1.7M. Notably, Invizyne Technologies's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invizyne Technologies is -- versus 21.61x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Invizyne Technologies's net margin of -49.65%. Invizyne Technologies's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Invizyne Technologies has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that NovaBay Pharmaceuticals has higher upside potential than Invizyne Technologies, analysts believe NovaBay Pharmaceuticals is more attractive than Invizyne Technologies.

Invizyne Technologies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Invizyne Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invizyne Technologies pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Invizyne Technologies quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Invizyne Technologies's net income of -$1.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Invizyne Technologies's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invizyne Technologies is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.